Full Year 2024 Altamira Therapeutics Ltd Earnings Call Transcript
Key Points
- Altamira Therapeutics Ltd (CYTOF) gained momentum in its RNA delivery programs by securing two new partners for its X4 platform.
- The company demonstrated the versatility of its platform by successfully working with circular RNA, opening new business opportunities.
- Altamira Therapeutics Ltd (CYTOF) filed a provisional patent application for its CycloPhore technology, which could attract collaborations in the circular RNA space.
- The company expanded its research and development team and moved to a new location with modern lab facilities, supporting its growing activities.
- Altamira Therapeutics Ltd (CYTOF) received a patent from the US Patent and Trademark Office for its Bentrio nasal spray, providing market protection up to 2040.
- Altamira Therapeutics Ltd (CYTOF) faced a major setback as NASDAQ decided to delist its common shares due to minimum bid price rule issues.
- The company's net loss for 2024 increased to $8.5 million compared to $4.3 million in the previous year.
- Altamira Therapeutics Ltd (CYTOF) had to transfer trading of its common shares to OTCQB, impacting valuation and trading volume.
- The company concluded that raising funding from public markets was not viable, leading to a focus on private equity investors.
- Operating expenses from continuing operations increased, with research and development expenses rising from $3.4 million in 2023 to $3.7 million in 2024.
Good day and welcome to the Altamira Therapeutics Full year 2024 Financial Results and Business update call. Today's conference is being recorded. I would now like to hand the conference over to your first speaker. Please go ahead.
Good morning and welcome to the Altamira Therapeutics full year 2024 financial results and business update call. On today's call are Thomas Thomas, Altamira's founder, Chairman and Chief Executive Officer, and Covadonga Paneda, Altamira's Chief Operating Officer.
Earlier today, Altamira issued a news release with the full year 2024 financial results as well as a business update.
The release is available on the company's website at www.Altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995. These include statements that address future operating, financial or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
